VectorY Therapeutics, an emerging bio­technology company focused on vectorized antibody therapies for neurodegenerative diseases, has appointed Dr. Olga Uspenskaya-Cadoz as Chief Medical Officer (CMO). The strategic appointment comes at a pivotal moment as the company prepares to submit an Investigational New Drug (IND) application for its lead candidate, VTx-002, for sporadic amyotrophic lateral sclerosis (ALS) […]

Bio-Rad Laboratories has achieved a significant regulatory milestone with EU Quality Management Systems certification under the In Vitro Diagnostic Regulation (IVDR), enabling CE marking for 40 infectious disease molecular quality control products from their Exact Diagnostics brand.

The equity-free accelerator programme, based in Basel’s life sciences hub, aims to address the 80% failure rate of healthtech startups by providing direct access to pharmaceutical expertise and resources.

German biotechnology company Navigo Proteins has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to accelerate development of targeted radiotheranostics. The partnership aims to combine Navigo’s expertise in precision carrier molecules with SCK CEN’s capabilities in radioisotope production and preclinical testing.

New research reveals over 3 million children died globally from AMR-related infections in 2022, with particular concerns about increasing use of critical antibiotic classes.